Tesaro Closes $101M
Biopharmaceutical company Tesaro Inc. has closed a whopping $101 million Series B round led by Kleiner Perkins Caufield & Byers. Existing shareholder New Enterprise Associates also participated, as did new investors InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management and Leerink Swann. Tesaro is focused on oncology-related products, including a drug to prevent chemotherapy-induced nausea. The company sealed a $20 million Series A round in 2010.
21 June 2011•5 mins read
